ArticleScience (New York, N.Y.)2018
Anti-CRISPRs on the march.
Article in Science (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Beyond DNA editing: how Cas13 redefined programmable RNA manipulation and what still limits its therapeutic promise.Nucleic acids research · 2026Review
- Expression level of anti-phage defence systems controls a trade-off between protection range and autoimmunity.Nature microbiology · 2025Article
- Treating genetic blood disorders in the era of CRISPR-mediated genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.Iranian journal of basic medical sciences · 2025Review
- Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies.International journal of nanomedicine · 2024Review
- CRISPR/Cas9 Genome Editing for Tissue-Specific In Vivo Targeting: Nanomaterials and Translational Perspective.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.Cancer communications (London, England) · 2022Review
- Spatiotemporal control of CRISPR/Cas9 gene editing.Signal transduction and targeted therapy · 2021Review
- Mapping CRISPR spaceromes reveals vast host-specific viromes of prokaryotes.Communications biology · 2020Article
- CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.Molecular cell · 2020Article
- Machine learning predicts new anti-CRISPR proteins.Nucleic acids research · 2020Article
- Evolutionary entanglement of mobile genetic elements and host defence systems: guns for hire.Nature reviews. Genetics · 2020Review
- A single-molecule counting approach for convenient and ultrasensitive measurement of restriction digest efficiencies.PloS one · 2020Article
- Bioinformatics Identification of Anti-CRISPR Loci by Using Homology, Guilt-by-Association, and CRISPR Self-Targeting Spacer Approaches.mSystems · 2019Article
- CRISPR-Cas in mobile genetic elements: counter-defence and beyond.Nature reviews. Microbiology · 2019Article
- Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research.Molecular therapy. Methods & clinical development · 2019Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30309933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.